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Abstract
Various methodological options exist on evaluating differences in both subgroups and the overall pop-
ulation. Most desirable is the simultaneous study of multiple endpoints in several populations. We
investigate a newer method using multiple marginal models (mmm) which allows flexible handling of
multiple endpoints, including continuous, binary or time-to-event data. This paper explores the perfor-
mance of mmm in contrast to the standard Bonferroni approach via simulation. Mainly these methods
are compared on the basis of their familywise error rate and power under different scenarios, varying in
sample size and standard deviation. Additionally, it is shown that the method can deal with overlapping
subgroup definitions and different combinations of endpoints may be assumed. The reanalysis of a
clinical example shows a practical application.
Keywords: subgroup analysis, multiple endpoints, simultaneous inference, adjusted confidence in-
tervals.
1 Introduction
The analysis of subgroups is challenging in randomized phase III clinical trials both for a priori defined
and post hoc selected subgroups. What is particularly challenging is the exact analysis and the appropriate
interpretation between global and subgroup-specific consideration [1]. Particularly, observed effect sizes
may differ between subgroups and therefore the interpretation of results can become ambitiously. What
does it mean when a subgroup shows a larger effect than the overall population? For instance Mok et. al.
[2] published a study, where the 0.64 upper confidence limit of the hazard ratio of progression-free sur-
vival in the EGFR-mutation positive subgroup reveals a substantially larger benefit compared with 0.85
limit in the overall population after treatment of patients with pulmonary adenocarcinoma with Gefitinib
compared with Carboplatin-Paclitaxel. A guideline was released by the EMA [3] focusing on the ex-
ploratory investigation of subgroups where the treatment effects are in line with the overall population or
show different if not contradictory results. Principally, it supports methods that take care of multiplicity
and are sensitive to treatment effects, so that a further assessment of efficacy is possible. Accordingly,
our focus lies upon the stringent requirement, that "It is highly unlikely that claims based on subgroup
analyses would be accepted in the absence of a significant effect in the overall study population" [4].
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Up to now controversies exist on several aspects, such as the inherently reduced power for subpopulations
or the need of an interaction test including the option to test for clinical relevance in components next to
the global null hypothesis. To alleviate the fact that interaction tests lack power, the choice of subgroups
must be sufficiently considered even more. Often it can be assumed that already a preferred subgroup
of interest exists. In the research of biomarkers, it is common for a subgroup to be composed only with
regard to the positive expression of a biomarker (B+) whereby the other set of observations merges into
a heterogeneous population of other cases. The latter are therefore not of equal interest and it would be
logically inconsistent to test them as a remaining subgroup [5]. This scenario is extended when there is
no or minimal effect on the entire population but a beneficial effect can be demonstrated in the targeted
subgroup. Using a fallback procedure that also accounts for the correlation between test statistics, both
the hypotheses of the overall study population and the subgroup may be tested once a pre-specified degree
of consistency is met [6]. Another scenario has to be considered when licensing for the total population
requires additionally to its own significance that the treatment effect in the complementary subgroup is
above a threshold. Otherwise, the claim is made for the targeted subgroup only (consistency constraint)
[7].
Alternatively, without restricting the alternative by any a priori assumptions we propose an union-intersection
test (UIT) principle that makes it possible to simultaneously test for a treatment effect in any combination
of populations to be studied, e.g. at least one subgroup or total population. The global null hypothesis of
neither effect in each population is contrasted against the alternatives of at least one - any one - significant
population or any patterns up to all significant populations. Clearly, that is a selected conservative ap-
proach whereas its conservativeness is reduced by taking the correlations of the test statistics into account.
The advantage is the availability for claims of any population patterns (e.g. global and targeted subgroup)
and, instead of adjusted p-values or alpha-propagation rules [8], the use of simultaneous confidence limits
for appropriately chosen effect sizes (see the recommendation in ICH E9 [9]).
Recently, a case study [10] was presented in which an oncology trial explores two primary endpoints,
progression-free survival after 2.5 years and overall survival after 4 years, and their examination in three
populations. Yet it is not uncommon to select multiple endpoints and further extend this interest in more
than one population. Consequently, we discuss the UITs for both some subgroups and multiple primary
endpoints without any restriction in importance. Specifically, a different scaling is allowed for different
endpoints.
This paper will compare the combination of marginal linear models mmm [11] by using the multivariate
normal or multivariate t distribution with a different choice of degrees of freedom in contrast to a simple
Bonferroni approach or multiple contrast test if the correlation structure between test statistics is known.
We investigate whether the methods control the familywise error rate in small sample situations and pro-
vide advantages in power. It is shown that mmm can deal with overlapping subgroup definitions and offers
an easy handling of multiple endpoints, also with different distributions or different scales, such as con-
tinuous, proportions or time-to-event data. Finally accounting for correlation leads to a benefit in power
compared to Bonferroni.
Section 3 provides a statistical framework for multiple pairwise comparisons used in this paper. Simu-
lation results for familywise error rate and power are examined in Section 4. An application of the mmm
method in R is illustrated in Section 5 by one clinical example. Section 6 concludes the article with a
discussion and a few comments.
2 A Case Study: the AVEROES trial
In a randomized two-arm trial Apixaban, a novel factor Xa inhibitor was compared with aspirin to re-
duce the risk of stroke or systemic embolism in patients with atrial fibrillation for the primary efficacy
outcome of stroke (ischaemic, haemorrhagic, or unspecified stroke). A predefined subgroup analysis was
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performed whether patients with previous stroke or transient ischaemic attack (S1) would show a greater
benefit from Apixaban than patients with no previous stroke or TIA (S2) [12]. In Table 1 the event data
in patients with and without a history of stroke or TIA is given in a dichotomous structure counting the
numbers of stroke or systemic embolism and no such an event for the total population, both subgroups and
the subordinated endpoints (Ischemic or unspecified stroke, Hemorrhagic stroke, and stroke in general).
Global S1 S2
Treatment Endpoint no Event Event no Event Event no Event Event
Apixaban Ischaemic 2764 43 381 9 2383 34
Aspirin 2692 97 347 27 2345 70
Apixaban Hemorrhag 2801 6 389 1 2412 5
Aspirin 2780 9 370 4 2410 5
Apixaban Stroke 2758 49 380 10 2378 39
Aspirin 2684 105 344 30 2340 75
Table 1: Selected effects of apixaban on efficacy outcomes in the full population and in patients with and without history of stroke or TIA
(transient ischaemic attack), taken from [12, p. 228].
3 Methods
We consider a two-way ANOVA model
Yijk = µij + ijk, 1 ≤ i ≤ m, 1 ≤ j ≤ l, 1 ≤ k ≤ nij , (1)
where yijk denotes the k-th observation in subgroup j of treatment group i, µij is the mean in subgroup
j of treatment group i and ijk are random independent and normally distributed errors. The treatment
factor has m levels with all groups i subdivided into l subgroups in which subgroup j contains nij
observations. It is assumed that with αi = µi. − µ, βj = µ.j − µ and (αβ)ij = µij − (µ+ αi + βj) the
model can be rewritten as
Yijk = µ+ αi + βj + (αβ)ij + ijk, (2)
where the parameter µ denotes the grand mean, αi corresponds to the main treatment effect in group i,
βj to the effect in subgroup j and (αβ)ij to the joint effect of the i-th level of the treatment factor and the
j-th level of the subgroup factor. We are then interested in the superiority of e.g. a new treatment in each
subgroup and the total population compared to placebo which can be expressed for the standard case of
m = 2 treatment groups and l = 2 subgroups by the null hypotheses
1. Htotal : α1 − α2 = 0 (no difference in total population)
2. Htarget : µ11 − µ21 = 0 (no difference in subgroup j = 1, denoted as targeted)
3. Hcompl : µ12 − µ22 = 0 (no difference in subgroup j = 2, denoted as complementary).
3.1 Multiple Marginal Models (mmm)
A flexible approach has been introduced by Pipper et al. [11] in which a set of statistical inferences
concerning the same sample can be assessed by a formulation of multiple marginal models. All models
can be evaluated simultaneously by estimating the correlation between the test statistics using a score
decomposition and hence no explicit formulation of the correlation is required.
For each model fit maximum likelihood estimators have asymptotic representations based on standardized
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score functions for observations [13, Theorem 5.21]. These asymptotic representations may be combined
into a multivariate asymptotic representation by stacking over all models (stacking is not destroying
independence). Convergence in distribution of the corresponding stacked parameter estimates is ensured
by the multivariate central limit theorem. Moreover, a consistent estimator of Σ may be obtained as
the empirical variance-covariance of the stacked standardized score functions. This asymptotic result
implies the following multivariate normal approximation to the family-wise error rate for test statistics
Zr (significance level α):
P (maxr=1,...,R|Zr| > z1−α/2)→ 1−
∫ z1−α/2
−z1−α/2
. . .
∫ z1−α/2
−z1−α/2
φ(s, 0, C)ds
= fC(α)
where z1−α/2 is the 1 − α/2 percentile in N(0, 1), φ the R-dim. multivariate normal density, and C
the variance-covariance matrix of (Z1, . . . , ZR). A consistent estimator of C is given by
Cˆ = diag(Σˆ)−1/2Σˆdiag(Σˆ)−1/2. We refer to [11] for additional details (including proofs of weak
and strong control of the family-wise error rate). The resulting multiplicity adjustment is always less
conservative than the Bonferroni adjustment (the larger the correlation between test statistics the larger
the gain).
Various statistical models can be used as marginal models. For example in the recently introduced event
of an overall model with all observations included and a number of smaller models for subsets of data i.e.
targeted and complementary subgroup where observations which do not belong to the subgroup are set to
missing. Basically in a case of two treatment arms (l+ 1) univariate linear models are fitted, one for each
subgroup comparison plus one for the inference decision in the global population.
For the standard example of one treatment group (trt) and one control group (ctrl) i.e. m = 2 treatment
groups with l = 2 subgroups the set of three fitted models is: 1) trt vs. ctrl with observations of the
second subgroup set to missing, 2) trt vs. ctrl with observations of the first subgroup set to missing and
3) trt vs. ctrl for the main effect with all observations available. P-values and confidence intervals can
be then adjusted using a reference distribution based on the estimated correlation matrix of those models.
In R the functions mmm() and glht() are implemented in the R package multcomp [14] for the
calculation of the correlation matrix and simultaneous testing of hypotheses respectively. In the basic
formulation of glht(), when no degrees of freedom are stated, results rely on a multivariate normal
distribution. Otherwise, degrees of freedom may be specified as an additional df argument to glht()
and the multivariate t distribution is used for the evaluation.
A complicating factor is added when the various patient subpopulations arise from overlapping subgroup
definitions which are not disjoint. This is obviously the case if several factors of interest exist and the
association is expressed dichotomously in yes/no, e.g. in biomarker studies or multiple nominal factors
are combined to one subgroup interpretation, for instance S1 : node-negative, no chemotherapy and
S2 : any nodal status, no chemotherapy [15]. Even more than one endpoint might be important in a
clinical study. Rather than defining one primary endpoint, several models can be established with respect
to different endpoints. Both complications of overlapping subgroups and multiple endpoints, even a
combination can be incorporated in individual model definitions in mmm.
Marginal models may not only be applied to linear models with Gaussian error terms. It also features
generalized linear models that have a non-normal error distribution like binomial, multinomial, poisson
or negative binomial distribution covering virtually all statistical circumstances. Furthermore mmm allows
for covariate adjustment with different covariance structure per endpoint or subgroup definition.
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3.2 Simulation
3.2.1 Two treatments and subgroups in the general linear model
For a start, we consider the simplest statistical setting of two equally sized treatment groups (m = 2) and
two subgroups (l = 2) for which we assume normality of the residuals and homogeneity of variance. To
assess potential differences in treatment the following test procedures are investigated in this paper. The
corresponding abbreviation used for the figures is named in italics.
No multiplicity adjustment (noadjust). This procedure of no adjustment in which the situation
of multiple comparisons is completely ignored is only included for completeness and does not control
the familywise error rate by definition. The p-values are calculated from a set of three marginal tests,
e.g. three t-tests, where one is for the main group difference (trt vs. ctrl) and one for each subgroup
comparisons (trttarget vs. ctrltarget and trtcompl vs. ctrlcompl). These p-values will be each compared
to a comparison-wise significance level of 0.05 (5%).
Bonferroni (bonferroni). Bonferroni correction is a fairly simple and still common way of handling
multiplicity in clinical studies and aims to control the familywise error rate although it is conservative.
The p-values derived from the three t-tests mentioned above (i.e. the nonadjust approach) will be com-
pared at α = 0.05/3. Correlation of the test statistics is completely ignored in this case.
Cell-means model (cellmeans). In this approach a fitted response model (1) with parameters (µ11, µ21, µ12, µ22),
which are called the cell means, and a contrast matrix C
C =
 −1 1 0 00 0 −1 1
− n11(n11+n12) n21(n21+n22) − n12(n11+n12) n22(n21+n22)

can be used to simultaneously test treatment effects within subgroups (first and second contrast) and
the main effect of treatment across subgroups (third contrast). Note that the elements of µ or columns
of C respectively are primarily ordered according to the subgroup, and within that factor according to
treatment. For the third contrast each mean of the treatment group is estimated by the mean of the
observations within the subgroups weighted according to their proportion of the treatment group. So
n11
(n11+n12)
µ11 +
n12
(n11+n12)
µ12 represents the weighted arithmetic mean of the means in subgroups 1 and
2 in the control group and the weights { n11(n11+n12) , n12(n11+n12)} are their proportional sample sizes in the
control. All p-values will be adjusted for multiple comparisons using the known correlation matrix and
the underlying trivariate t distribution [16]. In R this is made easy by the access of multcomp [14] on
the mvtnorm package ([17]).
Multiple Marginal Models (mmm). The approach of Multiple Marginal Models (mmm) calculates the
correlation between all test statistics using a score decomposition [11] and hence no explicit formulation
of the correlation is required. P-values will be adjusted using a reference distribution, based on the
estimated correlation matrix. In the basic formulation, when no degrees of freedom are given, results
rely on a multivariate normal distribution (mmm). If degrees of freedom are specified, for example, the
smallest degree of freedom of all models (mmm.dfmin), the largest degree of freedom of all models
(mmm.dfmax) or model specific degrees of freedom (mmm.dfind) multivariate t distribution is used for
the evaluation. This approach is implemented via mmm() in the R package multcomp and can be
customized by specifying df as an additional argument to glht().
3.2.2 Simulation structure
In a simulation study, we addressed the individual impact of different distribution parameters on the
familywise error rate and power for all considered methods. The sample size varied from small to large
with a total number of observations N = 20, 50, 100, 500 equally distributed to the treatment groups.
Since no heteroscedasticity was assumed, equal standard deviations were chosen for all subgroups varying
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in different scenarios as σ = (2, 5, 10). Moreover, we studied unbalanced subgroup sizes with various
proportions of the targeted subgroup ranging from 0.5 to 0.8 increased in constants of 0.1. The overall
mean was set to µ = 0 and an effect of δ = 0, . . . , 10 was added to each observation of the first subgroup
of the treatment group.
Multiple endpoints were generated from a bivariate normal distribution with the same assumptions from
above and different correlation parameters ρ = 0.2, . . . , 0.8.
To investigate the handling of overlapping subgroups a second subgroup definition was introduced with
same the expectation of subgroups ratios.
For each scenario, a number of 10000 datasets was generated and all comparisons of the treatment effect in
the subgroups and in the overall population were tested according to each method. Since all comparisons
were false for δ = 0 the proportion of datasets, in which at least one significant difference was detected
for any comparisons ("any") or for the targeted subgroup or the whole population ("targeted or total"),
represents the familywise error rate of the method. The power was estimated as the proportion of cases
with at least one hypothesis in any comparison correctly rejected. All simulations were performed in R,
version 3.2.1 [18].
4 Simulation Results
Figure 1: Simulated familywise error rate for simultaneous test procedures when testing for different sets of hypotheses. Comparison of the
estimated familywise error rate among two sets of hypotheses: first, that there is a difference in the whole population (Htotal) and the targeted
subgroup (Htarget) labelled by "targeted or total" in the top row and second, that there is a difference in the whole population and in both of the
subgroups labeled by "any" in the bottom row. All rates are assessed for different sample sizes and averaged over unbalanced subgroup sizes and
varying standard deviations under homoscedasticity. The total sample sizeN was equally distributed to the two treatment groups. The a priori chosen
alpha level of 0.05 is represented by the horizontal red dotted line.
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4.1 Type I error in the simultaneous analysis of multiple subgroups
To determine the extent to which the approaches identify an effect between the treatments, it should first
of all not be important whether this difference is present in the total population or in one of the subgroups.
In case that just one subgroup is of interest, this subset is referred to as targeted. This means that the null
hypothesis is tested in the total population and in the targeted subpopulation only and at least one of these
hypotheses is rejected to consider significance. Otherwise all subgroups are included in the definition of
the hypotheses and are examined at the same time. Results of the simulation study will be compared for
all procedures, which have been described in the methods section in detail, with respect to the preservation
of the familywise error rate given moderate or large sample sizes. Continuous endpoints are examined
first. An overlap of subgroups is incorporated next and multiple endpoints are examined in addition. The
power is only shown for those methods that control for the probability of making a type I error.
4.1.1 Concerning one targeted subgroup.
Figure 1 illustrates the estimated familywise error rates of the simultaneous test procedures averaged
across different parameter settings like varying standard deviations and subgroup populations. In the up-
per row, the type I error is shown in the case of testing for significant differences in the whole population
and the targeted subgroup. The simulation results are shown depending on the total number of observa-
tions N and differ by the test procedure. In a situation of multiple comparisons, no adjustment shows
harsh violations of the familywise error rate. Taking into account the multiplicity issue all mmm methods
exceed the 0.05 level in situations with small treatment groups except for mmm.dfmin which specifies
the smallest degree of freedom. Clearly, it is shown that mmm is an asymptotic procedure and best suitable
for large sample sizes. Its performance can be improved by using a multivariate t reference distribution.
For example mmm.dfind shows a familywise error rate near the 0.05 level for all sample sizes and is less
conservative than the Bonferroni adjustment. Likewise the cellmeans model controls the FWER
to full exploitation.
4.1.2 Concerning any subgroup.
In case that no subgroup is preferred the estimated familywise error rates are illustrated in the second row
of Figure 1 (any). Since all comparisons must be taken into account the results are slightly inflated than
these for the first simulation study. From a sample size of 250 subjects per group (N = 500) onwards
the estimated type I error levels off at α = 0.05 for all mmm adjustment procedures based on correlation
estimation. For lower sample sizes the methods show heterogeneous results depending on the before
specified degree of freedom. mmm.dfind slightly exceeds the type I error. Again the cellmeans
model controls the FWER.
4.2 Simultaneous analysis of several overlapping subgroup definitions
On condition of overlapping subgroups the cellmeans method is not considered any further for it
cannot deal with more than one single simultaneous model. Therefore Figure 2 illustrates the methods of
no adjustment, numerous t-tests with Bonferroni correction and mmm only. In all cases, the estimated type
I error is above the chosen alpha level of 0.05 when using no adjustment. Applying Bonferroni to a set
of t-tests is highly conservative while both methods mmm.dfmin and mmm.dfind achieve rates below
α = 0.05 already for a total sample size of N = 50. The same is true for the simulation in the whole set
of hypotheses.
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Figure 2: Simulated familywise error rate for simultaneous test procedures for two overlapping subgroups. Comparison of the estimated
familywise error rate in case of two overlapping subgroup definitions but one primary endpoint for both families of hypotheses, first that there is
a difference in the whole population and the targeted subgroup and second, that there is a difference in the whole population and in both of the
subgroups. The rates are calculated for different sample sizes and averaged over unbalanced subgroup sizes and varying standard deviations under
homoscedasticity. The total sample sizeN was equally distributed to the two treatment groups. The a priori chosen alpha level of 0.05 is represented
by the horizontal red dotted line.
4.3 Simultaneous analysis of several endpoints
Often even more than one endpoint is of major interest in clinical trials. In Figure 3 two continuous,
highly correlated endpoints (ρ = 0.8) endpoints are considered and tested in each of the individual
populations. Again mmm provides an easy handling of multiple endpoints and accounts for multiplic-
ity among correlated continuous endpoints. Simulations show similar results: Still the FWER is con-
trolled by Bonferroni for two endpoints but stays conservative in comparison to other multiplicity
approaches. With increasing sample sizes the mean estimated familywise error rate of all mmm methods,
mmm.dfind in particular, rapidly reduces to the predetermined alpha level.
4.4 Power of mmm
Having demonstrated which methods provide adequate protection against a familywise type I error it is
now examined whether these methods differ in terms of statistical power. Therefore this section focuses
on relevant methods only, namely Bonferroni, cellmeans and mmm.dfind for multiple subgroups
according to one endpoint and mmm.dfind compared with Bonferroni for the analysis of the second
simulation study regarding two correlated endpoints.
The probabilities to discover a false hypothesis in the primary scenario of one single endpoint regarding
multiple non-overlapping subgroups are illustrated in Figure 4 for different parameter settings like varying
standard deviations and sample sizes averaged across different subgroup populations when testing for
significant differences in the whole population or the targeted subgroup or any population. For larger
sample sizes, the power of all methods with multiplicity adjustment is as expected. Major differences in
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Figure 3: Simulated familywise error rate for simultaneous test procedures when testing for a set of hypotheses regarding two continuous
endpoints. Comparison of the estimated familywise error rate first among the two hypotheses that there is a difference in the whole population and
the targeted subgroup and second among all hypotheses that there is a difference in the whole population and in both of the subgroups. The rates are
calculated regarding two continuous, highly correlated endpoints (ρ = 0.8) for different sample sizes and averaged over unbalanced subgroup sizes
and varying standard deviations under homoscedasticity. The total sample size N was equally distributed to the two treatment groups. The a-priori
chosen alpha level of α = 0.05 is represented by the horizontal red dotted line.
power occur, the smaller the sample size is. For example, the gain of power for a total sample size of
N = 50 is 5.47% when one chooses mmm.dfind compared to the combination of several t-tests with
Bonferroni adjustment (sd = 10). Even bigger is the advantage when using the cellmeans model
instead, e.g. at a sample size of N = 20. Here the benefit reaches up to 13.8% (sd = 2) as a gain in
power. At a sample size of N = 50, the numeric gain is still more than 6%. Figure 5 represents a similar
analysis for the case of multiple endpoints and multiple subgroups. Especially when a strong correlation
between endpoints exists the new method mmm.dfind shows a substantial benefit in power. Thus, the
power curves of highly correlated endpoints (ρ = 0.80) are displayed. In these a power advantage up to
8.35% (sd = 5) and 8.50% (sd = 10) can be retrieved, e.g. for a sample size of N = 50.
5 Case Study Analysis
The treatment effect of each endpoint comparing Apixaban versus Aspirin as the reference group and
their 95% confidence intervals are shown in Figure 6. Although Apixaban reduced the risk of stroke and
ischaemic or unspecified stroke in the full population and in both subgroups, no further benefit can be
demonstrated for the efficacy endpoint of haemorrhagic stroke. The subgroup analysis of hemorrhagic
stroke in patients with previous stroke or TIA has a point estimate of 4.21, and its lower bound of the
one-sided confidence interval is at 0.3 (p = 0.39). The results in the total population show a point estimate
of 1.51 with a confidence interval that ranges from [0.44, Inf] (p = 0.65), indicating that the events for
patients receiving Apixaban are not significantly lower than for patients receiving Aspirin.
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Figure 4: Simulated power for simultaneous test procedures when testing for hypotheses regarding one continuous endpoint. Comparison
of the estimated power among two sets of hypotheses: first, that there is a difference in the whole population (Htotal) and the targeted subgroup
(Htarget) labelled by "targeted or total" in the top row and second, that there is a difference in the whole population and in both of the subgroups
labelled by "any" in the bottom row. All rates are assessed for different sample sizes and averaged over unbalanced subgroup sizes. The different line
types of the power curves relate to different standard deviations, which are assumed homogeneously in the treatments groups, starting with sd = 2 at
the top, sd = 5 in the middle and sd = 10 below. The total sample size N was equally distributed to the two treatment groups. The a-priori chosen
alpha level of 0.05 is represented by the horizontal red dotted line.
6 Discussion
Randomized clinical trials should be interpreted by appropriately chosen effect sizes and their simultane-
ous confidence intervals, whereas p-values should be avoided [9]. Therefore we propose a UIT-approach
allowing all possible patterns of alternatives for total, targeted and complementary subgroups. The cost
of such multiple testing is conservativeness whereas it is reduced (with respect to Bonferroni) by taking
the correlations between the test statistics into account.
Using the mmm approach marginal models can be formulated as generalized linear mixed-effects models
allowing the analysis of various primary endpoints occurring in RCTs, including multiple primary end-
points - even different scaled [19]. It controls the familywise error rate in simulations with a total sample
size of greater than or equal to 500. For smaller sample sizes this method is recommended with an extra
declaration of model specific degrees of freedom (mmm.dfind).
Extensions to multi-armed clinical trials are possible, e.g. using Dunnett procedure for comparing various
treatments against placebo. Of course, no increasing power can be achieved with respect to cell-means
model (only compared for non-overlapping subgroups). On the other hand, our new technique shows a
remarkable power increase compared to the standard Bonferroni adjustment. The same applies to
the case of overlapping subgroup definitions. The performance of the marginal models was generally
superior in terms of exploitation of alpha and power. By means of the function "mmm" in the R package
multcomp this approach is easily available, even for several types of (multiple) primary endpoints. Also
the use of Cox models is possible but has not been shown here [20].
While the detailed simulations of this paper demonstrate a wide range of application possibilities in set-
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Figure 5: Simulated power for simultaneous test procedures when testing for hypotheses regarding two continuous correlated endpoints.
Comparison of the estimated power among two sets of hypotheses: first, that there is a difference in the whole population (Htotal) and the targeted
subgroup (Htarget) labelled by "targeted or total" in the top row and second, that there is a difference in the whole population and in both of the
subgroups labelled by "any" in the bottom row. Endpoints were simulated with a correlation of ρ = 0.8. All rates are assessed for different sample
sizes and averaged over unbalanced subgroup sizes. The different line types of the power curves relate to different standard deviations, which are
assumed homogeneously in the treatments groups, starting with sd = 2 at the top, sd = 5 in the middle and sd = 10 below. The total sample sizeN was
equally distributed to the two treatment groups. The a priori chosen alpha level of 0.05 is represented by the horizontal red dotted line.
tings with multiplicity issues, further investigations may be constructive. Especially interesting is this
novel approach for cases where the explicit formulation of the covariance matrix is difficult or not avail-
able. We currently consider unbalanced designs with serious heterogeneity for further research on that
topic.
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Figure 6: One-sided simultaneous confidence intervals for the Odds Ratio of the AVERROES trial. Confidence intervals are based on the
approach of marginal models taking correlations into account.
A Appendix
A.1 Data structure and program code
For evaluation the dataset has to be in a form with one observation row per subject and each measurement
as a different column, where one column identifies the treatment variable as a factor, one specifies the
subgroup attribute and others contain the quantitative values for each endpoint (e.g. "Ischemic", "Hem-
orrhag", "Stroke") with a binary indicator depending on their manifestation, e.g. 1 for yes and 0 for no.
New variables for every endpoint must be defined for each subgroup in order to set the other subgroup
to NA. For example does I.noTIA include all data of the variable "Ischemic", only that all values of
the other subgroup (patients with previous stroke or TIA) are set to missing. The mmm() command is
implemented in package multcomp [14], which provides a framework for general linear hypotheses and
multiple comparisons in parametric models. For the comparison with a control group, Apixaban vs. As-
pirin, a Dunnett definition is used in the calling of mcp() and later passed as a list of linear functions to
mlf(). Due to the aspect that one is interested in lower event rates in the Apixaban group and therefore
positive treatment differences, the alternative hypothesis "greater" is specified.
library(multcomp)
# global
f1 <- glm(Ischemic ~ Treatment, data=trialdata, family=binomial())
f2 <- glm(Hemorhag ~ Treatment, data=trialdata, family=binomial())
f3 <- glm(Stroke ~ Treatment, data=trialdata, family=binomial())
# TIA (S1)
f4 <- glm(I.TIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
f5 <- glm(H.TIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
f6 <- glm(S.TIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
# No TIA (S2)
f7 <- glm(I.noTIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
f8 <- glm(H.noTIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
f9 <- glm(S.noTIA ~ Treatment, data=trialdata, na.action = na.exclude, family = binomial)
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# marginal MCT
fes1 <- glht(f1, mcp(Treatment = "Dunnett"), alternative="greater")
fes2 <- glht(f2, mcp(Treatment = "Dunnett"), alternative="greater")
fes3 <- glht(f3, mcp(Treatment = "Dunnett"), alternative="greater")
fes4 <- glht(f4, mcp(Treatment = "Dunnett"), alternative="greater")
fes5 <- glht(f5, mcp(Treatment = "Dunnett"), alternative="greater")
fes6 <- glht(f6, mcp(Treatment = "Dunnett"), alternative="greater")
fes7 <- glht(f7, mcp(Treatment = "Dunnett"), alternative="greater")
fes8 <- glht(f8, mcp(Treatment = "Dunnett"), alternative="greater")
fes9 <- glht(f9, mcp(Treatment = "Dunnett"), alternative="greater")
# mmm
msCI <- glht(mmm(f1,f2,f3,f4,f5,f6,f7,f8,f9), mlf(mcp(Treatment = "Dunnett")), alternative="greater")
A.2 Simultaneous analysis of the AVERROES trial
effect size noadjust Bonferroni mmm
Group Endpoint OR 95% CI p 95% CI p 95% CI p
Global Ischemic 2.32 [1.71-Inf) 0.0000 [1.45-Inf) 0.0000 [1.50-Inf) 0.0000
Hemorhag 1.51 [0.63-Inf) 0.2169 [0.40-Inf) 1.0000 [0.44-Inf) 0.6519
Stroke 2.22 [1.67-Inf) 0.0000 [1.43-Inf) 0.0000 [1.47-Inf) 0.0000
S1 (TIA) Ischemic 3.29 [1.73-Inf) 0.0012 [1.22-Inf) 0.0106 [1.31-Inf) 0.0077
Hemorhag 4.21 [0.67-Inf) 0.0999 [0.24-Inf) 0.8990 [0.30-Inf) 0.3861
Stroke 3.43 [1.86-Inf) 0.0004 [1.34-Inf) 0.0040 [1.43-Inf) 0.0031
S2 (noTIA) Ischemic 2.09 [1.48-Inf) 0.0002 [1.22-Inf) 0.0021 [1.27-Inf) 0.0013
Hemorhag 1.00 [0.35-Inf) 0.4995 [0.20-Inf) 1.0000 [0.23-Inf) 0.9404
Stroke 1.95 [1.41-Inf) 0.0004 [1.18-Inf) 0.0035 [1.22-Inf) 0.0025
Table 2: Simultaneous inference for the AVERROES trial. One-sided p-values and confidence intervals are computed by fitting a generalized linear
model, accounting for multiplicity using Bonferroni and by the mmm method taking correlations into account.
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A.3 Type I error in the simultaneous analysis of multiple subgroups
N prop_targ noadjust ttest cellmeans mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.0859 0.0458 0.0495 0.0886 0.0652 0.0436 0.0525
20 0.6 0.0800 0.0414 0.0480 0.0790 0.0584 0.0410 0.0483
20 0.7 0.0826 0.0435 0.0511 0.0812 0.0607 0.0465 0.0526
20 0.8 0.0834 0.0418 0.0517 0.0813 0.0593 0.0465 0.0523
50 0.5 0.0836 0.0443 0.0519 0.0636 0.0557 0.0478 0.0511
50 0.6 0.0817 0.0451 0.0522 0.0620 0.0553 0.0503 0.0529
50 0.7 0.0747 0.0392 0.0498 0.0582 0.0504 0.0480 0.0489
50 0.8 0.0701 0.0364 0.0488 0.0556 0.0494 0.0479 0.0489
100 0.5 0.0804 0.0456 0.0504 0.0559 0.0532 0.0496 0.0515
100 0.6 0.0803 0.0424 0.0508 0.0555 0.0522 0.0494 0.0510
100 0.7 0.0765 0.0397 0.0504 0.0566 0.0515 0.0495 0.0503
100 0.8 0.0707 0.0362 0.0508 0.0546 0.0509 0.0502 0.0506
500 0.5 0.0840 0.0425 0.0499 0.0520 0.0506 0.0496 0.0498
500 0.6 0.0750 0.0395 0.0490 0.0494 0.0487 0.0484 0.0484
500 0.7 0.0779 0.0425 0.0532 0.0542 0.0536 0.0530 0.0534
500 0.8 0.0705 0.0365 0.0501 0.0509 0.0504 0.0503 0.0504
1000 0.5 0.0880 0.0455 0.0521 0.0528 0.0527 0.0523 0.0525
1000 0.6 0.0843 0.0447 0.0544 0.0541 0.0535 0.0534 0.0534
1000 0.7 0.0754 0.0414 0.0523 0.0529 0.0524 0.0521 0.0521
1000 0.8 0.0724 0.0395 0.0529 0.0531 0.0531 0.0531 0.0531
Table 3: Simulated familywise error rate for simultaneous test procedures when testing for Htotal or Htarget. A cutout of the simulated
familywise error rates for the hypothesesHtotal orHtarget at sd = 5 with the total sample sizeN equally distributed to the two treatment groups.
Rates are assessed for unbalanced subgroup proportions where "prop_targ" indicates the proportion of the targeted subgroup in the total population.
N prop_targ noadjust ttest cellmeans mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.1254 0.0455 0.0553 0.1147 0.0845 0.0415 0.0583
20 0.6 0.1184 0.0432 0.0487 0.1078 0.0763 0.0394 0.0523
20 0.7 0.1221 0.0452 0.0559 0.1176 0.0866 0.0374 0.0587
20 0.8 0.1162 0.0420 0.0486 0.1141 0.0873 0.0328 0.0543
50 0.5 0.1168 0.0430 0.0501 0.0690 0.0593 0.0471 0.0524
50 0.6 0.1199 0.0432 0.0506 0.0718 0.0606 0.0458 0.0523
50 0.7 0.1210 0.0445 0.0503 0.0746 0.0653 0.0419 0.0540
50 0.8 0.1146 0.0412 0.0532 0.0841 0.0735 0.0338 0.0524
100 0.5 0.1105 0.0387 0.0476 0.0562 0.0512 0.0456 0.0474
100 0.6 0.1129 0.0403 0.0471 0.0572 0.0522 0.0466 0.0495
100 0.7 0.1116 0.0394 0.0459 0.0560 0.0519 0.0425 0.0465
100 0.8 0.1119 0.0401 0.0488 0.0644 0.0600 0.0398 0.0501
500 0.5 0.1122 0.0400 0.0478 0.0489 0.0485 0.0476 0.0477
500 0.6 0.1147 0.0414 0.0504 0.0527 0.0516 0.0498 0.0506
500 0.7 0.1084 0.0390 0.0493 0.0500 0.0489 0.0470 0.0488
500 0.8 0.1092 0.0362 0.0480 0.0497 0.0486 0.0454 0.0471
1000 0.5 0.1175 0.0387 0.0478 0.0482 0.0478 0.0473 0.0476
1000 0.6 0.1148 0.0400 0.0485 0.0503 0.0500 0.0494 0.0493
1000 0.7 0.1110 0.0403 0.0506 0.0508 0.0502 0.0489 0.0491
1000 0.8 0.1110 0.0379 0.0487 0.0495 0.0493 0.0474 0.0489
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Table 4: Simulated familywise error rate for simultaneous test procedures when testing for any hypotheses. A cutout of the simulated familywise
error rates for any hypotheses ofHtotal, Htarget, Hcompl at sd = 5 with the total sample sizeN equally distributed to the two treatment groups.
Rates are assessed for unbalanced subgroup proportions where "prop_targ" indicates the proportion of the targeted subgroup in the total population.
A.4 Type I error in case of two overlapping subgroup definitions
N prop_targ noadjust ttest mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.1299 0.0434 0.1180 0.0828 0.0454 0.0586
20 0.6 0.1124 0.0393 0.0968 0.0673 0.0394 0.0485
20 0.7 0.1157 0.0412 0.0965 0.0690 0.0438 0.0536
20 0.8 0.1065 0.0413 0.0920 0.0658 0.0469 0.0537
50 0.5 0.1129 0.0410 0.0671 0.0585 0.0467 0.0508
50 0.6 0.1097 0.0409 0.0690 0.0595 0.0518 0.0546
50 0.7 0.0984 0.0384 0.0630 0.0556 0.0509 0.0527
50 0.8 0.0925 0.0312 0.0591 0.0501 0.0476 0.0484
100 0.5 0.1185 0.0416 0.0589 0.0546 0.0490 0.0516
100 0.6 0.1077 0.0379 0.0550 0.0511 0.0479 0.0490
100 0.7 0.0974 0.0366 0.0579 0.0527 0.0510 0.0513
100 0.8 0.0926 0.0321 0.0584 0.0547 0.0538 0.0538
500 0.5 0.1110 0.0406 0.0514 0.0507 0.0493 0.0497
500 0.6 0.1062 0.0384 0.0531 0.0524 0.0513 0.0515
500 0.7 0.0939 0.0362 0.0505 0.0497 0.0492 0.0493
500 0.8 0.0951 0.0358 0.0562 0.0556 0.0552 0.0553
1000 0.5 0.1148 0.0429 0.0533 0.0529 0.0525 0.0526
1000 0.6 0.1075 0.0392 0.0506 0.0505 0.0503 0.0503
1000 0.7 0.0994 0.0367 0.0529 0.0525 0.0525 0.0525
1000 0.8 0.0918 0.0338 0.0530 0.0527 0.0523 0.0524
Table 5: Simulated familywise error rate for simultaneous test procedures when testing for Htotal or Htarget in a dataset with two over-
lapping subgroups. A cutout of the simulated familywise error rates in case of two overlapping subgroup definitions but one primary endpoint for
the hypotheses Htotal or Htarget at sd = 5 with the total sample size N equally distributed to the two treatment groups. Rates are assessed for
unbalanced subgroup proportions where "prop_targ" indicates the proportion of the targeted subgroup in the total population.
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N prop_targ noadjust ttest mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.1826 0.0437 0.1381 0.0933 0.0439 0.0599
20 0.6 0.1862 0.0421 0.1459 0.0950 0.0433 0.0615
20 0.7 0.1794 0.0437 0.1442 0.0963 0.0397 0.0615
20 0.8 0.1750 0.0425 0.1457 0.0971 0.0363 0.0611
50 0.5 0.1714 0.0423 0.0780 0.0639 0.0475 0.0537
50 0.6 0.1708 0.0387 0.0792 0.0653 0.0421 0.0520
50 0.7 0.1748 0.0443 0.0934 0.0793 0.0445 0.0603
50 0.8 0.1688 0.0395 0.1000 0.0860 0.0326 0.0546
100 0.5 0.1643 0.0386 0.0615 0.0555 0.0481 0.0503
100 0.6 0.1708 0.0399 0.0640 0.0591 0.0491 0.0524
100 0.7 0.1662 0.0366 0.0627 0.0560 0.0408 0.0479
100 0.8 0.1701 0.0384 0.0742 0.0684 0.0393 0.0507
500 0.5 0.1724 0.0399 0.0505 0.0499 0.0491 0.0493
500 0.6 0.1753 0.0435 0.0592 0.0578 0.0561 0.0567
500 0.7 0.1661 0.0412 0.0553 0.0541 0.0517 0.0533
500 0.8 0.1638 0.0352 0.0527 0.0518 0.0462 0.0483
1000 0.5 0.1682 0.0386 0.0484 0.0484 0.0480 0.0481
1000 0.6 0.1664 0.0389 0.0516 0.0506 0.0508 0.0503
1000 0.7 0.1714 0.0367 0.0490 0.0491 0.0472 0.0481
1000 0.8 0.1625 0.0369 0.0522 0.0520 0.0503 0.0513
Table 6: Simulated familywise error rate for simultaneous test procedures when testing for any hypotheses. A cutout of the simulated familywise
error rates in case of two overlapping subgroup definitions but one primary endpoint for any hypotheses of Htotal, Htarget, Hcompl at sd = 5
with the total sample sizeN equally distributed to the two treatment groups. Rates are assessed for unbalanced subgroup proportions where "prop_targ"
indicates the proportion of the targeted subgroup in the total population.
A.5 Type I error in the simultaneous analysis of multiple endpoints
N prop_targ noadjust ttest mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.1342 0.0373 0.1055 0.0715 0.0423 0.0560
20 0.6 0.1265 0.0332 0.0943 0.0611 0.0402 0.0513
20 0.7 0.1254 0.0365 0.0923 0.0623 0.0456 0.0550
20 0.8 0.1228 0.0367 0.0869 0.0584 0.0483 0.0546
50 0.5 0.1287 0.0380 0.0679 0.0572 0.0456 0.0510
50 0.6 0.1255 0.0354 0.0651 0.0551 0.0495 0.0523
50 0.7 0.1197 0.0333 0.0643 0.0534 0.0493 0.0515
50 0.8 0.1124 0.0323 0.0622 0.0536 0.0518 0.0528
100 0.5 0.1344 0.0337 0.0608 0.0552 0.0489 0.0514
100 0.6 0.1235 0.0351 0.0564 0.0529 0.0499 0.0516
100 0.7 0.1169 0.0324 0.0555 0.0505 0.0494 0.0505
100 0.8 0.1092 0.0270 0.0513 0.0472 0.0463 0.0464
500 0.5 0.1262 0.0372 0.0522 0.0512 0.0501 0.0506
500 0.6 0.1192 0.0337 0.0507 0.0500 0.0496 0.0499
500 0.7 0.1208 0.0350 0.0526 0.0517 0.0514 0.0515
500 0.8 0.1078 0.0293 0.0497 0.0489 0.0488 0.0489
1000 0.5 0.1254 0.0339 0.0485 0.0481 0.0477 0.0478
1000 0.6 0.1181 0.0336 0.0496 0.0490 0.0488 0.0488
1000 0.7 0.1171 0.0330 0.0495 0.0489 0.0487 0.0486
1000 0.8 0.1059 0.0273 0.0473 0.0468 0.0468 0.0469
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Table 7: Simulated familywise error rate for simultaneous test procedures when testing for Htotal or Htarget in a dataset with two 0.8
correlated endpoints. A cutout of the simulated familywise error rates in case of two continuous endpoints with a correlation of ρ = 0.8 for the
hypotheses Htotal or Htarget at sd = 5 with the total sample size N equally distributed to the two treatment groups. Rates are assessed for
unbalanced subgroup proportions where "prop_targ" indicates the proportion of the targeted subgroup in the total population.
N prop_targ noadjust ttest mmm mmm.dfmax mmm.dfmin mmm.dfind
20 0.5 0.1342 0.0373 0.1055 0.0715 0.0423 0.0560
20 0.6 0.1265 0.0332 0.0943 0.0611 0.0402 0.0513
20 0.7 0.1254 0.0365 0.0923 0.0623 0.0456 0.0550
20 0.8 0.1228 0.0367 0.0869 0.0584 0.0483 0.0546
50 0.5 0.1287 0.0380 0.0679 0.0572 0.0456 0.0510
50 0.6 0.1255 0.0354 0.0651 0.0551 0.0495 0.0523
50 0.7 0.1197 0.0333 0.0643 0.0534 0.0493 0.0515
50 0.8 0.1124 0.0323 0.0622 0.0536 0.0518 0.0528
100 0.5 0.1344 0.0337 0.0608 0.0552 0.0489 0.0514
100 0.6 0.1235 0.0351 0.0564 0.0529 0.0499 0.0516
100 0.7 0.1169 0.0324 0.0555 0.0505 0.0494 0.0505
100 0.8 0.1092 0.0270 0.0513 0.0472 0.0463 0.0464
500 0.5 0.1262 0.0372 0.0522 0.0512 0.0501 0.0506
500 0.6 0.1192 0.0337 0.0507 0.0500 0.0496 0.0499
500 0.7 0.1208 0.0350 0.0526 0.0517 0.0514 0.0515
500 0.8 0.1078 0.0293 0.0497 0.0489 0.0488 0.0489
1000 0.5 0.1254 0.0339 0.0485 0.0481 0.0477 0.0478
1000 0.6 0.1181 0.0336 0.0496 0.0490 0.0488 0.0488
1000 0.7 0.1171 0.0330 0.0495 0.0489 0.0487 0.0486
1000 0.8 0.1059 0.0273 0.0473 0.0468 0.0468 0.0469
Table 8: Simulated familywise error rate for simultaneous test procedures when testing for any hypotheses in a dataset with two 0.8 correlated
endpoints. A cutout of the simulated familywise error rates in case of two continuous endpoints with a correlation of ρ = 0.8 for any hypotheses
of Htotal, Htarget, Hcompl at sd = 5 with the total sample size N equally distributed to the two treatment groups. Rates are assessed for
unbalanced subgroup proportions where "prop_targ" indicates the proportion of the targeted subgroup in the total population.
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